Kornimate/medical-research-clean huggingface dataset:
kidney and pregnancy registry

Conditions: Kidney Diseases

Summary: maternal physiological adaptation to pregnancy plays an important role in the smooth progress of the pregnancy and the healthy growth of the fetus. this physiological adaptation takes place at the level of several organs, including the kidney. physiological changes during a normal pregnancy take place at the anatomical, glomerular and tubular level. in the event of pre-existing kidney damage (glomerular and tubular diseases, stone disease, high blood pressure (hypertension) etc...) these adaptations will not be optimal. this will have implications for: * the course of the pregnancy with the occurrence of feto-maternal complications: miscarriages, pre-eclampsia, intrauterine growth retardation (iugr), low birth weight, prematurity. the risk of feto-maternal complications increases with the degree of renal failure or with certain pathologies such as lupus. * progression of kidney disease some maternal complications have long-term implications: preeclampsia is associated with a high risk of subsequent cardiovascular and renal complications. pregnancies in these patients are high-risk pregnancies and require specialized management by an experienced group of gynecologists and nephrologists. the creation of a retrospective and prospective register by collecting demographic, clinical, biological, radiological and genetic data concerning patients at each consultation within the chu brugmann hospital will allow: * to establish the epidemiological and clinico-biological characteristics of the patients followed at the kidney and pregnancy clinic at the chu brugmann hospital * to analyze the risk factors for feto-maternal complications * to analyze the risk factors for the occurrence of subsequent cardio-renal pathologies in patients who have had preeclampsia or an event during their pregnancy * to identify patients who will need specialized genetic testing


Eligibility criteria:
inclusion criteria: 1. pre-conception consultations woman of childbearing age with: * renal damage (glomerular, tubular disease, renal lithiasis, systemic disease, metabolic diseases, congenital diseases, etc.) * hematological disorders (sickle cell disease) * kidney transplantation * high blood pressure (hypertension) * pre-kidney transplant assessment in progress for discussion of contraception and pregnancy after kidney transplantation * preeclampsia * multiple miscarriages * iugr and low birth weight in the fetus * family history of kidney disease 2. peri-gravid consultations pregnant women with * pre-existing kidney damage * de novo renal failure (ir) * proteinuria * hematuria * chronic hypertension * pregnancy hypertension * renal lithiasis 3. postpartum consultations postpartum women with * early/late pre-eclampsia * eclampsia / hemolysis elevated liver enzymes low platelet (hellp) syndrome * pregnancy hypertension * postpartum hemorrhage * de novo renal failure postpartum exclusion criteria: male patients menopausal patients
a novel approach to enhance true recovery after stroke

Conditions: Stroke; Inpatients; Recovery of Function; Observational Study

Summary: the purpose of this study is to elucidate pathophysiological mechanisms behind gait disturbances during the early recovery phase after hemiparetic stroke to identify targets for new treatment strategies. using an explorative, observational study design, pathophysiological mechanisms at play during the early recovery phase will be monitored, by repeated clinical assessments during inpatient rehabilitation as well as examinations of muscle activation patterns, kinematics of walking, corticospinal and reticulospinal function \< 1 month, 3 and 6 months after hemiparetic stroke. inclusion: eligible patients will have suffered a stroke, verified by ct or mri examination and are admitted to inpatient care at the university department of rehabilitation medicine danderyd hospital (ruds). thirty patients will be included consecutively. with an anticipated loss of 4-10 patients, at least 20 are expected to complete the study. the clinical assessment protocols include standardized measures for the assessment of clinical and self-perceived aspects of functioning and disability. these assessments will be performed and repeated \< 1 month, at 3 months and 6 months post-stroke by a therapist not responsible for rehabilitation interventions. at each of these assessment instances, laboratory movement analysis including electromyography (emg) and ultrasound of the lower extremity muscle will be performed. in addition, a short assessment of body function and activity will be performed weekly during inpatient rehabilitation.


Eligibility criteria:
inclusion criteria: * participants with hemiplegia, dependence in ambulation (1- 4 according to the functional ambulation categories (fac)), * \>= 50 points on the trunk control test. * impaired dorsiflexion manifested as impaired voluntarily dorsiflexion and inability to hold the ankle in a dorsiflexed position while sitting, and for ambulatory participants, impaired dorsiflexion during swing phase and initial contact during visual inspection of gait. * recommended for an ancle foot orthosis (afo) by an experienced physiotherapist. able to understand study information and provide informed consent. exclusion criteria: * contracture that severely restricts gait movements in a lower limb joint, * cardiovascular or other somatic condition incompatible with intensive gait training, * notifiable infectious disease, contagious infections (e.g. mrsa or esbl) * inability to participate in the rehabilitation intervention due to behavioral or psychiatric disorder * when magnetic resonance imaging will be performed, additional exclusion criteria are current or history of epilepsy, metal implants in the brain/skull cochlear implants, any implanted neurostimulator, cardiac pacemaker or cardiac implants of metal and infusion device.
fever tracking study

Conditions: Core Body Temperature in Healthy Subjects; Immune Response to mRNA COVID-19 Vaccination

Summary: the aim of this study is to investigate the feasibility of continuous fever tracking of participants having fever symptoms in a home setting, using a core body temperature (cbt) sensor. cbt as measured by the wearable sensors will be coampared with cbt as measured by ingestible electronc pills (reference). a secondary research question is, if the cbt behavior of the the participants in a home setting can be compared to previously described cbt profiles in the literature, and if special patterns can be identified.


Eligibility criteria:
inclusion criteria: * age 18-60 years old * informed consent signed * either: acute fever symptoms at inclusion (at least 38.0°c) and test for covid-19 at the day of inclusion - or: second shot or booster of mrna covd-19 vaccination (comirnaty® or covid-19 vaccine moderna®) at day of inclusion exclusion criteria: * any participant who, for any reason, is unable to independently consent to participate in the study and/or who is unable to independently follow the study protocol. * any participant with previous surgical procedures in the gastrointestinal tract * inability to swallow pills * any participant of ≤40 kg body weight * a scheduled mri examination in the period from the start of the measurements until seven days after ingestion of the electronic pill. * any participant being pregnant * impairment or disability of the upper extremity likely to have a negative impact on the quality of measurements: * wounds * active venous access * amputations * dialysis shunt * edema * axillary dissection * continuous long-term monitoring of blood pressure * tattoos * known allergy to plastics / latex * language problems

Keywords: fever tracking core body temperature cbt mrna covid-19 vaccination wearable sensors wearables
red blood cell transfusion in very premature infants and has 2014 guideline

Conditions: Practice Guideline of Erythrocyte Transfusion in Preterm Infant

Summary: the indications that motivated the decision to transfuse (or not) were analyzed to verify compliance with has recommendations. medical records from 57 premature infants \< 32 weeks hospitalized between 2016 -2017 were retrospectively analysed, especially all the events related to monitoring of hemoglobin level and rbc transfusions during the first month of life. the criteria (postnatal age, rate of haemoglobin, type of breathing assistance, oxygen needing, medullary regeneration) on which rely the decision process in the has algorithm for the rbc transfusion were also considered, as well as the final decision actually adopted for each case (transfused/ not transfused). all this made it possible to determine the kappa coefficient for evaluation of agreement with has new guidelines in the investigator's medical staff.


Eligibility criteria:
inclusion criteria: * preterm infant hospitalized in amiens school hospital (chu amiens-picardie) between october 2016 and april 2017 during the first month of life, with allowed access on data recorded in medical files concerning the evolution of clinical characteristics (body weight,...) and the results of laboratory analyses performed during this initial hospital stay. exclusion criteria: * less than 25 weeks or more than 32 weeks at birth * any hemoglobin dosage during the hospital stay * serious congenital malformation * known or documented neonatal red blood cell disease (inherited hemolysis, enzymopathy of red blood cell membrane,...)

Keywords: red blood cell transfusion preterm infant has guideline transfusion guidelines kappa agreement test application
safety and efficacy study of hybrid revascularization in multivessel coronary artery disease

Conditions: Heart Disease; Myocardial Ischaemia; Coronary Disease; Coronary Artery Disease

Summary: the purpose of the study is to assess the safety and efficacy of hybrid revascularization in comparison with coronary artery bypass grafting among patients with multivessel coronary artery disease.


Eligibility criteria:
inclusion criteria: * age 18 or more * angiographically confirmed multivessel cad with involved lad and critical (\>70%)lesion in at least one (apart lad) major epicardial vessel amenable to both pci and cabg * indication for revascularization based upon symptoms of angina and/or objective evidence of myocardial ischaemia * patient is willing to comply with all follow-up visits * patient signed an informed consent exclusion criteria: * severe congestive heart failure (class iii or iv according to nyha, or pulmonary edema, cardiogenic shock) at the time of enrollment * prior surgery with the opening of pericardium or pleura * prior stroke (within 6 months)or more than 6 months if there are substantial neurological defects * prior history of significant bleeding (within previous 6 months) that might be expected to occur during pci/cabg related anticoagulation * one or more chronic total occlusions in major coronary territories * left main stenosis (at least 50% diameter stenosis) * acute st-elevation mi within 72 hours prior to enrollment requiring revascularization * planned simultaneous surgical procedure unrelated to coronary revascularization (e.g. valve repair/replacement, aneurysmectomy, carotid endarterectomy or carotid stenting) * contraindication to either cabg, midcab or pci/des because of a coexisting clinical condition * significant leukopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis. * intolerance or contraindication to aspirin or both clopidogrel and ticlopidine * extra-cardiac illness that is expected to limit survival to less than 5 years e.g. oxygen-dependent chronic obstructive pulmonary disease, active hepatitis or significant hepatic failure, severe renal disease * suspected pregnancy. a pregnancy test will be administered prerandomization to all women of child-bearing age * concurrent enrollment in another clinical trial * patient inaccessible for follow-up visits required by protocol

Keywords: multivessel coronary artery disease hybrid revascularization coronary artery bypass grafting percutaneous coronary interventions drug eluting stents
immunotherapy in upper tract urothelial carcinoma

Conditions: Urothelial Carcinoma

Summary: upper-tract urothelial carcinoma (utuc) is a rare tumor. standard treatment of localized disease is most often radical nephroureterectomy. in advanced/metastatic disease, treatments follow the standards for urothelial carcinoma including platinum-based chemotherapy and anti-pd(l)1 (programmed death (ligand) 1) immunotherapy, with no regard as to the primary disease site (bladder or upper tract). given the rarity of utuc, efficacy data in the utuc subgroup of advanced urothelial carcinoma is scarce. utuc show distinct pahological and molecular features, including higher prevalence of microsatellite instability and of abnormalities in the fgfr (fibroblast growth factor receptors) gene family. these specific features may impact outcomes of immunotherapy in advanced/metastatic utuc.


Eligibility criteria:
inclusion criteria: * age 18 and more * diagnosis of urothelial carcinoma (with or without variant histology) * advanced/metastatic disease not amenable to local treatment with curative intent * treatment with an anti-pd-(l)1 monoclonal antibody initiated between 2016 and 2022 exclusion criteria: * patient's opposition to this research * urothelial carcinoma of bladder or urethral primary site * non-urothelial tumor * maintenance immunotherapy initiated without disease progression
platelet rich fibrin versus platelet rich plasma for microneedling treatment of facial photoaging

Conditions: Photoaging

Summary: the present study was conducted for analyzing the efficacy and safety of platelet-rich plasma (prp) and platelet-rich fibrin (prf) in photoaging therapy. specific arms: 1. the investigators will compare the photoaging improvement of prf and prp treated face before and after treatment by two blinded investigators. 2. the investigators will evaluate the improvement of each parameter of photoaging by visia system, dermoscope, and optical coherence tomography. 3. the investigators will evaluate the safety of the treatment of prf and prp. each case will receive 3 sessions of injection therapies with one month interval (t0, t1, and t2). each case will receive prp therapy on one side of the face and prf on the other side of face. the investigators will determine the treatment method for both sides of each case randomly by coin flapping before the study. the investigators will evaluate each case before each session of therapy (t0, t1, t2) as well as 1 (t3) and 3 months (t4) after final session of treatment.


Eligibility criteria:
inclusion criteria: 1. men or female patients older than 20 years old with facial photoaging (glogau scale type ii) 2. the photoaging severity of bilateral face is symmetric. exclusion criteria: 1. patients with thrombocytopenia, coagulopathy, hematopoietic malignancy. 2. patients with severe inflammation over treated area, malignancy, keloid, or poor wound healing history. 3. patients had received laser, radiofrequency, ultherapy over treated area within 6 months. 4. patients had received botulism or filler injection over treated area within 12 months. 5. patients had received plastic surgery over treated area within 12 months. 6. patients had severe psychiatric disorders with poor control. 7. patients with other diseases which are not suitable for receiving platelet rich plasma (prp) or platelet rich fibrin (prf) therapy.

Keywords: photoaging platelet rich plasma platelet rich fibrin
improving neonatal health through rapid malaria testing in early pregnancy with high-sensitivity diagnostics

Conditions: Malaria,Falciparum; Malaria in Pregnancy; Malaria in Childbirth; Pregnancy; Neonatal Health; Low Birthweight; Stillbirth; Gestational Age and Weight Conditions; Preterm Birth

Summary: the purpose of the intrepid study is to compare 1st trimester screening for malaria parasites with a high-sensitivity malaria rapid diagnostic test followed by treatment of test-positive women with artemether-lumefantrine (al) against usual antenatal care on a composite adverse pregnancy outcome including low birth weight, small for gestational age, preterm, fetal loss, or neonatal death.

intrepid is a two-arm, open-label, parallel-assignment randomized trial of a strategy of 1st trimester screening for p. falciparum parasites with a high-sensitivity rapid diagnostic test (hs-rdt). participants will be women of all gravidities presenting to antenatal clinics in the 1st trimester in sites endemic for p. falciparum malaria in kenya and the democratic republic of the congo. following consent and enrollment, women will be allocated 1:1 to either usual antenatal care or to the intervention. the intervention will be a single screening in the 1st trimester for p. falciparum infection in maternal peripheral blood with a hs-rdt. women who test positive for p. falciparum on hs-rdt testing will be treated with a single course of artemether-lumefantrine (al) and then returned to usual antenatal care. participants will be followed through delivery and then through their offspring's first month of life. the hypothesis is that, compared to usual antenatal care, screening women in the 1st trimester for p. falciparum and treating them if positive with al will reduce the risk of an adverse pregnancy outcome.

Eligibility criteria:
inclusion criteria: * aged between 16 years and 40 years (inclusive) * viable singleton pregnancy with gestational age estimated less than 13 6/7 weeks (inclusive) by ultrasound * hiv-uninfected * willing to participate in the study schedule * planning to remain in the study area for the duration of pregnancy and 1 month after delivery * willing to deliver in a study-affiliated health facility exclusion criteria: * high risk pregnancy that requires referral for specialized care by local guidelines * active medical problem at the time of screening requiring higher level care * antimalarial receipt in the 2 weeks prior to screening * past allergy to artemether or lumefantrine or another condition that prohibits the receipt of either drug * current participation in another clinical research study
review of french cases of glutathione synthetase deficiency

Conditions: The Glutathione Synthetase Deficiency

Summary: the glutathione synthetase deficiency, inborn error of metabolism of autosomal recessive inheritance, is a rare disease (70 patients described in the world). the outcome of these patients and potential complications of this disease are not, to date, yet all known and described.


Eligibility criteria:
inclusion criteria: * all patients followed in the french hospital centers the diagnosis of glutathione synthetase deficiency has been proven by assay of residual enzyme activity or identifying a mutation of the glutathione synthetase gene exclusion criteria: * no formal proof of glutathione synthetase deficiency

Keywords: glutathione glutathione synthetase deficiency autosomal inheritance recessive
feasibility study of zetafuse(tm) bone graft in the repair of bone defects from metastatic breast cancer in the spinal vertebral body

Conditions: Metastatic Breast Cancer in the Spine

Summary: zetamet™ (zetafuse™ bone graft) is indicated for patients with destructive, lytic lesions due to metastatic breast cancer to bone, with or without involvement of other sites, with at least one metastatic lesion located in a vertebral body of the spine, and a spinal instability neoplastic score (sins) ≥3 and ≤9. zetamet™ (zetafuse™ bone graft) is percutaneously implanted into the bone defect created by the metastatic tumor in a spinal vertebral body. zetamet™ (zetafuse™ bone graft) is only for implantation into the vertebral body.

this is an open-label single-arm study. subjects (n=10) will be recruited from up to 4 investigational sites in canada. key inclusion criteria are metastatic breast cancer to bone with at least one lytic metastatic lesion located in a vertebral body of the spine and a sins ≥3 and ≤9. zetamet™ (zetafuse™ bone graft) will be percutaneously implanted into the vertebral body defect(s) created by the lytic metastatic tumor. post-operative care will be per standard of care (soc) at the investigational site. subjects will be followed for 180 days post-treatment. if post-surgical radiation treatment is planned, it should not occur for at least 84 days post-surgery to allow for bone formation.

Eligibility criteria:
inclusion criteria: * age between 22 (inclusive) and 75 years (inclusive) at the time of enrollment. * life expectancy of 12 months or more. * female patient with histologically confirmed diagnosis of primary breast cancer. * metastatic breast cancer to bone, with or without involvement of other sites (patients with single metastasis qualify) * at least one lytic metastatic lesion located in the vertebral body of the spine. * normal spinal alignment. * sins ≥3 and ≤9. * signed and dated informed consent form (icf). * patient is willing and able to participate in required follow-up visits at the investigational site and to complete study procedures and questionnaires. exclusion criteria: * vertebral body collapse. * spinal cord compression. * known allergy to investigational device materials. * using medications or any drug known to potentially interfere with bone/soft tissue healing (e.g., chronic systemic steroids). * current tobacco smoker or stopped smoking in past 6 months. * uncontrolled diabetes mellitus, hbaic cutoff. * an active systemic infection (e.g., hepatitis, acquired immunodeficiency syndrome (aids), aids-related complex (arc). * currently participating in any investigational trial not related to this trial. * any other severe acute or chronic medical condition that may interfere with the interpretation of the trial results, in the judgment of the pi, which would make the patient inappropriate for entry into this trial. * pregnant or planning to become pregnant during the trial.

Keywords: metastatic breast cancer bone metastases spine metastases vancouver metastatic breast cancer to bone x-radiation therapy
trial comparing proximal tibia and proximal humerus infusion rates using the nio intraosseous device

Conditions: Intraosseous Access; Resuscitation

Summary: the investigators sought to compare the intraosseous access success rates of the proximal tibia and the proximal humerus using new intraosseous access device "nio" in an adult cadaver model during simulated resuscitation.


Eligibility criteria:
inclusion criteria: * give voluntary consent to participate in the study * paramedics * without previous experience in intraosseous devices exclusion criteria: * not meet the above criteria

Keywords: intraosseous access cardiopulmonary resuscitation paramedic simulation cadaver